Chemistry42: An AI-Driven Platform for Molecular Design and Optimization.


Journal

Journal of chemical information and modeling
ISSN: 1549-960X
Titre abrégé: J Chem Inf Model
Pays: United States
ID NLM: 101230060

Informations de publication

Date de publication:
13 02 2023
Historique:
pubmed: 3 2 2023
medline: 15 2 2023
entrez: 2 2 2023
Statut: ppublish

Résumé

Chemistry42 is a software platform for

Identifiants

pubmed: 36728505
doi: 10.1021/acs.jcim.2c01191
pmc: PMC9930109
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

695-701

Références

J Med Chem. 2010 Apr 8;53(7):2719-40
pubmed: 20131845
Mol Pharm. 2018 Oct 1;15(10):4398-4405
pubmed: 30180591
Bioinformatics. 2015 Feb 1;31(3):405-12
pubmed: 25301850
ACS Med Chem Lett. 2020 Jul 14;11(8):1496-1505
pubmed: 32832015
Cell Cycle. 2017;16(17):1578-1584
pubmed: 28594262
J Med Chem. 2019 Nov 27;62(22):10026-10043
pubmed: 31188596
Nat Commun. 2016 Nov 16;7:13427
pubmed: 27848968
Nat Commun. 2018 Feb 21;9(1):741
pubmed: 29467463
Front Pharmacol. 2020 Dec 18;11:565644
pubmed: 33390943
Mol Inform. 2018 Jan;37(1-2):
pubmed: 29319225
Nat Biotechnol. 2019 Sep;37(9):1038-1040
pubmed: 31477924
Oral Oncol. 2019 Sep;96:77-88
pubmed: 31422218
J Chem Inf Model. 2018 Jun 25;58(6):1194-1204
pubmed: 29762023
Nat Rev Drug Discov. 2015 Jun;14(6):387-404
pubmed: 25907346
J Chem Inf Model. 2013 Aug 26;53(8):1967-78
pubmed: 23845061
Trends Pharmacol Sci. 2019 Nov;40(11):806-809
pubmed: 31629547
J Cell Commun Signal. 2019 Jun;13(2):163-177
pubmed: 30666556
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Oncotarget. 2017 Feb 14;8(7):10883-10890
pubmed: 28029644
Mol Inform. 2018 Jan;37(1-2):
pubmed: 29442446
Mol Pharm. 2017 Sep 5;14(9):3098-3104
pubmed: 28703000
ACS Cent Sci. 2018 Jan 24;4(1):120-131
pubmed: 29392184
Drug Discov Today. 2018 Jun;23(6):1241-1250
pubmed: 29366762
Chem Rev. 2019 Sep 25;119(18):10520-10594
pubmed: 31294972

Auteurs

Yan A Ivanenkov (YA)

Insilico Medicine Kong Kong Ltd., Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, Hong Kong.

Daniil Polykovskiy (D)

Insilico Medicine Canada Inc., 3710-1250 René-Lévesque Blvd W, Montreal, Quebec, H3B 4W8 Canada.

Dmitry Bezrukov (D)

Insilico Medicine Kong Kong Ltd., Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, Hong Kong.

Bogdan Zagribelnyy (B)

Insilico Medicine AI Limited, Level 6, Unit 08, Block A, IRENA HQ Building, Masdar City, PO Box 145748, Abu Dhabi, UAE.

Vladimir Aladinskiy (V)

Insilico Medicine AI Limited, Level 6, Unit 08, Block A, IRENA HQ Building, Masdar City, PO Box 145748, Abu Dhabi, UAE.

Petrina Kamya (P)

Insilico Medicine Canada Inc., 3710-1250 René-Lévesque Blvd W, Montreal, Quebec, H3B 4W8 Canada.

Alex Aliper (A)

Insilico Medicine AI Limited, Level 6, Unit 08, Block A, IRENA HQ Building, Masdar City, PO Box 145748, Abu Dhabi, UAE.

Feng Ren (F)

Insilico Medicine Shanghai Ltd., Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.

Alex Zhavoronkov (A)

Insilico Medicine Kong Kong Ltd., Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, Hong Kong.

Articles similaires

Selecting optimal software code descriptors-The case of Java.

Yegor Bugayenko, Zamira Kholmatova, Artem Kruglov et al.
1.00
Software Algorithms Programming Languages

Exploring blood-brain barrier passage using atomic weighted vector and machine learning.

Yoan Martínez-López, Paulina Phoobane, Yanaima Jauriga et al.
1.00
Blood-Brain Barrier Machine Learning Humans Support Vector Machine Software
Humans Artificial Intelligence COVID-19 SARS-CoV-2 Pandemics

Classifications MeSH